Research programme: lysosomal storage disorder therapeutics - Calporta

Drug Profile

Research programme: lysosomal storage disorder therapeutics - Calporta

Latest Information Update: 14 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan
  • Developer Calporta Therapeutics; University of Michigan
  • Class Small molecules
  • Mechanism of Action MCOLN1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Niemann-Pick disease type C

Most Recent Events

  • 15 Jun 2015 Early research in Niemann-Pick disease type C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top